Samjin Pharmaceutical삼진제약
005500 · KOSPI · ₩005500 · 삼진제약
₩19,240▼ ₩70 (0.36%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩309B | ₩308B | ₩292B | ₩274B | ₩250B |
| Cost of sales | ₩184B | ₩179B | ₩175B | ₩156B | ₩132B |
| Gross profit | ₩125B | ₩129B | ₩117B | ₩118B | ₩118B |
| Operating income | ₩27B | ₩32B | ₩20B | ₩23B | ₩34B |
| Net income | ₩24B | ₩39B | ₩19B | ₩21B | ₩28B |
| Net income to shareholders | ₩24B | ₩39B | ₩19B | ₩21B | ₩28B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩471B | ₩425B | ₩420B | ₩405B | ₩332B |
| Current assets | ₩192B | ₩159B | ₩146B | ₩134B | ₩140B |
| Cash and equivalents | ₩12B | ₩3.4B | ₩2.4B | ₩2.3B | ₩7.9B |
| Total liabilities | ₩180B | ₩164B | ₩155B | ₩130B | ₩98B |
| Current liabilities | ₩147B | ₩159B | ₩145B | ₩82B | ₩50B |
| Borrowings | ₩135B | ₩120B | ₩118B | ₩78B | ₩50B |
| Total equity | ₩290B | ₩262B | ₩265B | ₩275B | ₩234B |
| Shareholders' equity | ₩290B | ₩262B | ₩265B | ₩275B | ₩234B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩24B | ₩38B | ₩8.3B | ₩18B | ₩24B |
| Free cash flow | ₩24B | ₩38B | ₩8.3B | ₩18B | ₩24B |
| Dividends paid | ₩9.8B | ₩10B | ₩11B | ₩9.8B | ₩9.8B |
Consolidated where available. Amounts in won.
Also known as: Samjin Pharmaceutical / 삼진제약 / 005500 / KRX:005500
Source: KRX statistical information